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Left ventricular assist devices (LVAD) are a currently established destination and bridge therapy until cardiac
transplantation; hence, this patient population continues to increase. Here, we present the first report of abdominal
aortic cross-clamping (ACC) in a LVAD patient undergoing emergency aneurysm repair. Anticoagulation was continued
pre-and intra-operatively to avoid pump thrombosis. The pumping function of the LVAD is highly dependent on both
preload and afterload. In this case, abdominal ACC, which increases the afterload, did not significantly influence circulatory
dynamics. However, when the abdominal ACC was released, mean atrial pressure (MAP) fell to 42 mmHg, because
preload reduction due to massive bleeding (3532 g) secondary to anticoagulation and afterload reduction by
abdominal ACC release combined to cause critical hypotension. Maintenance of MAP required rapid infusion and
use of an alpha-adrenergic agent. Surgical and anesthesia times were 411 and 525 min, respectively. Total blood
loss was 5389 g, respectively. The patient was discharged after 25 postoperative days with no major complications.
ACC release, with its accompanying decrease in preload and afterload, and massive bleeding due to anticoagulation in
these patients require careful management.
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The presence of implanted left ventricular assist devices
(LVAD) presents a dilemma when managing other serious
medical problems in this patient population [1, 2]. Al-
though there are some reports of anesthetic management
in patients with LVAD undergoing non-cardiac surgery
[3–8], this is the first report of abdominal aortic cross-
clamping (ACC) performed in a patient with a LVAD,
which is known to be sensitive to preload and afterload.Case presentation
Written informed consent was obtained from the pa-
tient for publication of this Case report. The patient
was a 51-year-old male (height 171 cm, weight 60 kg).
He had had cardiac resynchronization therapy with a
defibrillator device implanted 2 years earlier, as well as a
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International License (http://creativecommo
reproduction in any medium, provided you
link to the Creative Commons license, and iimplanted 6 months earlier for ischemic cardiomyop-
athy. Concurrent anticoagulation therapy included war-
farin and aspirin. He was urgently admitted to the
hospital on the day prior to surgery due to infected
pseudoaneurysms of the bilateral common iliac arteries,
which were deemed suitable for Y-shaped graft replace-
ment. Preoperative transthoracic echocardiography dis-
played an ejection fraction of 5 %. As his PT-INR was
3.28, warfarin was discontinued and an infusion of heparin
2000 U/day was commenced 1 day before surgery.
In the operating room, the patient was monitored for
ECG, pulse oximetry, arterial blood pressure, central ven-
ous pressure (CVP), transesophageal echocardiography
(TEE), and bispectral index (BIS). The LVAD parameters
were as follows: pump speed, 8200 rpm; calculated flow,
4–5 L/min; pump power, 5–6 W. The patient’s anesthetic
record is shown in Fig. 1. Heart rhythm was a mixture of
spontaneous and pacemaker rhythm (AAI, HR 60). Hep-
arin 2000 U/h was continued during the surgery.
Anesthesia was induced with fentanyl 100 μg, remifentanil
0.3 μg/kg/min, midazolam 10 mg, and rocuronium 60 mg,e is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
ndicate if changes were made.
Fig. 1 Anesthetic record. Pheny phenylephrine, HR heart rate, ART (M) mean arterial pressure, CVP (M) central venous pressure, EtCO2 end-tidal carbon
dioxide, ACT activated clotting time, RCC red cell concentrate, FFP fresh frozen plasma, ACC aortic cross-clamping,☓ start and completion of anesthesia,
T intubation,◎ start and completion of surgery
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0.1–0.3 μg/kg/min, and fentanyl 1300 μg. Hypotension
was treated with intermittent boluses of phenylephrine
(0.05–0.1 mg). When the infrarenal abdominal ACC was
applied under the same LVAD conditions, MAP and CVP
increased from 61 to 71 mmHg and from 5 to 6 mmHg,
respectively. ACC time was 124 min. During ACC, bleed-
ing, the source of which could not be pinpointed, contin-
ued. Before ACC release, the volume of blood lost was
3532 g, and the volumes of fluid (including colloid solu-
tions) and red cell concentrate (RCC) infusions were 5400
and 1680 ml, respectively. When the ACC was released,
MAP decreased to 42 mmHg, and a decrease in the size
of both ventricles was observed on TEE, but the sucking
phenomenon was not observed. The calculated flow of the
LVAD also decreased to 3 L/min. We requested the sur-
geon to re-clamp the aorta and re-release it gradually.
Simultaneously, acute massive transfusion, fluid infusion,
and administration of phenylephrine (total 0.4 mg) were
performed for maintenance of MAP. Further, an infusion
of norepinephrine (0.1–0.15 μg/kg/min) was started. Withthis, MAP increased to 60 mmHg, and calculated LVAD
flow returned to 5 L/min within 15 min. At this time, the
values of pH and base excess were 7.354 and −2.4, respect-
ively. Thereafter, the heparin infusion was stopped, and
10 mg of protamine was administered. Surgical and
anesthesia times were 411 and 525 min, respectively. Total
blood loss and urine output were 5389 g and 1507 ml, re-
spectively. The volumes of fluid, RCC and fresh frozen
plasma (FFP) infusions were 7200, 2520, and 960 ml,
respectively.
The patient was transferred to the intensive care unit
and extubated the next day. He was discharged 25 days
later with no major complications.
The hemodynamic management of LVAD patients dur-
ing non-LVAD surgery is important because the pump
function depends on both preload and afterload [9]. Con-
tinuous flow LVADs are up to three times more sensitive
to a change in afterload compared with normal heart
function [10]. Therefore, in this case, we were anxious
about the hemodynamics at the time of ACC application
and release. However, application of the ACC did not
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to be due to the venodilatation and relative dehydration
resulting from anesthesia induction. Another reason for
this may have been the fact that HeartMate II is an axial
pump, and axial pumps are less afterload sensitive than
centrifugal pumps [11]. On the other hand, when the
ACC was released, MAP decreased precipitously. This
could be because ACC release pathophysiologically de-
creased both afterload and venous return [12]. It has been
reported that HeartMate II, in particular, demonstrates in-
creased preload sensitivity in the low-afterload region as
compared to other LVADs [11]. In this case, blood loss in-
creased rapidly 30 min before ACC release, together with
a fall in CVP. Ideally, we should have started adequate
preloading and infusion of an alpha-adrenergic agent be-
fore ACC release. Moreover, a pulmonary artery catheter
should have been used to monitor actual cardiac output,
since the calculated flow shown on the system console
may not always have a high degree of fidelity with the pa-
tient’s true cardiac output [13]. It is possible to perform
this surgery using cardiopulmonary bypass. The advantage
of cardiopulmonary bypass is that to achieve stable circu-
latory dynamics, and the disadvantage is to increase op-
erative stress.
LVAD patients chronically require anticoagulation to
avoid pump thrombosis [3, 14]. In this case, because
ACC required systemic heparinization, heparin was
continued. Hemostasis, on the other hand, required dis-
continuation of heparin, administration of protamine,
and FFP transfusion. A previous report suggests that the
risk of bleeding due to impaired platelet aggregation in
HeartMate II-treated patients may be significant [15].
Hence, the anesthetic management of LVAD patients
should include a plan against massive bleeding pre-
operatively using FFP and platelet concentrates, while
balancing intra-operative bleeding with pump throm-
bosis. Anticoagulant management is likely to be even
more challenging when these patients present for emer-
gency surgery.
RV dysfunction is another potential cause of reduced
LVAD output. Thus, maintaining RV function in LVAD
patients undergoing surgical procedures is extremely im-
portant. This can be achieved pharmacologically by a
combination of inotropes and RV afterload reducers. We
achieved this by using dobutamine, and avoiding in-
creases in pulmonary vascular resistance (e.g., due to
hypoxemia, hypercarbia, and acidosis).
Conclusions
This is the first report of abdominal ACC performed in a
LVAD patient sensitive to preload and afterload. Applica-
tion of the ACC did not significantly affect circulatory dy-
namics, although its release caused a marked decrease in
MAP. ACC release, with its accompanying decrease inpreload and afterload, and massive bleeding due to anti-
coagulation in these patients require careful management.
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